1833.HK Ping An Healthcare HKSE HK$13.78 intraday: earnings 11 Feb may reset price

The 1833.HK stock trades at HK$13.78 intraday on 06 Feb 2026 as investors position ahead of Ping An Healthcare and Technology Company Limited’s earnings on 11 Feb 2026. Volume sits at 1,958,700.00 shares, below the 50-day average, while the stock is off 1.71% for the session. Traders should focus on revenue growth, EPS of HK$0.10, and whether guidance or margin trends change the market view.

1833.HK stock earnings timing and what to expect

Ping An Healthcare and Technology (1833.HK) reports results on 11 Feb 2026. The upcoming report will be the primary catalyst for the stock and is likely to address user growth, monetisation of online medical services, and contribution from medicine sales and hospital services. Reuters notes ongoing coverage of the company ahead of the release source.

Intraday price action and short-term trading context for 1833.HK stock

Intraday the stock opened at HK$13.93, hit a low of HK$13.55 and a high of HK$13.93 with current price HK$13.78. Average daily volume is 16,572,641.00, so today’s 1,958,700.00 shares represent low liquidity. The 50-day average is HK$15.09 and the 200-day average is HK$13.43, leaving the stock near its medium-term trend line.

Valuation and fundamentals driving 1833.HK stock analysis

The company reports EPS of HK$0.10 and a trailing PE of 139.30, reflecting high market expectations. Key ratios: price-to-sales 5.04, price-to-book 2.53, current ratio 3.15, and free cash flow per share 0.14. Net margin is 3.05%, and growth metrics show fiscal 2024 revenue growth of 2.88%, suggesting modest top-line momentum against a premium valuation.

Meyka AI rates 1833.HK with a score out of 100 and forecast

Meyka AI rates 1833.HK with a score out of 100 — score 69.95, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of HK$17.11, quarterly HK$17.09, and yearly HK$20.87. Versus the current HK$13.78, the yearly projection implies an upside of 51.45%; monthly implies 24.17%. Forecasts are model-based projections and not guarantees.

Technical signals and momentum for 1833.HK stock

Momentum indicators show the stock is near overbought territory with RSI 71.57 and Stochastic %K 88.30. MACD is 0.53 with signal 0.20, supporting a short-term bullish trend but higher volatility; ATR is 0.75. Bollinger Bands sit at Lower HK$12.61, Middle HK$14.76, Upper HK$16.90, suggesting limited upside without a catalyst.

Risks, catalysts and sector context for 1833.HK stock

Key risks: premium valuation (PE 139.30), reliance on China user growth, and regulatory changes in healthcare. Catalysts include stronger-than-expected service monetisation, margin improvement, or successful clinic integrations. Healthcare sector performance in Hong Kong has been mixed; investors should weigh sector peers and ETF flows such as KWEB holdings source.

Final Thoughts

Key takeaways for the 1833.HK stock: the immediate driver is the earnings release on 11 Feb 2026, which could validate the premium valuation or trigger a re-rate. At HK$13.78, the stock trades close to its 200-day average with a trailing PE of 139.30 and EPS of HK$0.10, so expectations are high. Meyka AI’s model projects a yearly price of HK$20.87, implying a 51.45% upside versus today, though short-term technicals show overbought signals. Our view: treat positions as event-driven into earnings, size positions for volatility, and monitor revenue growth and margin commentary closely. Meyka AI is an AI-powered market analysis platform that models scenarios but forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.